H.C. Wainwright analyst Emily Bodnar has reiterated their neutral stance on AGEN stock, giving a Hold rating on March 12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the recent financial performance and strategic outlook of Agenus. The company reported a slight increase in collaboration revenue for the fourth quarter of 2024, but a significant reduction in operating expenses, which was more than anticipated. This cost reduction is largely attributed to a decrease in headcount and a shift in clinical programs to investigator-sponsored trials. Despite these efforts, Agenus faces the challenge of needing to initiate late-stage trials or find a partner to advance its indications toward FDA approval.
Furthermore, the valuation and risks associated with Agenus contribute to the Hold rating. The necessity for a large Phase 3 trial to support the approval of their bot/bal treatment in MSS-CRC is expected to delay potential approval and require substantial capital. The current valuation includes a 30% probability of success for this treatment, but does not account for other pipeline assets. Additional risks include potential safety issues, lower-than-expected efficacy, increased competition, regulatory concerns, and significant financing needs projected through 2037.
In another report released on March 12, Robert W. Baird also maintained a Hold rating on the stock with a $3.00 price target.